NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03247088 |
Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Acute Myeloid Leukemia
|
Drug: Sorafenib
Drug: Busulfan
Drug: Fludarabine
Procedure: Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Filgrastim
|
M.D. Anderson Cancer Center
Bayer |
Phase 1
Phase 2 |
NCT03246958 |
Nivolumab Plus Ipilimumab in Thyroid Cancer |
Thyroid Cancer |
Drug: Nivolumab
Drug: Ipilimumab |
Dana-Farber Cancer Institute
Bristol-Myers Squibb |
Phase 2 |
NCT03246906 |
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation |
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggressive Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma|....
|
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Drug: Sirolimus |
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI) |
Phase 2 |
NCT03245892 |
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer |
High Grade Serous Ovarian
Fallopian Tube
Primary Peritoneal Cancer |
Drug: Carboplatin and Paclitaxel
Drug: Nivolumab
Procedure: cytoreductive surgery |
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb |
Phase 1 |
NCT03245736 |
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors |
Ovary Cancer|Cervix Cancer
Endometrium Cancer
Bladder Cancer
Prostate Cancer... |
Drug: Tisotumab Vedotin |
Genmab |
Phase 2 |